anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Background: Physical distancing and visiting restrictions during the COVID-19 pandemic particullarly posed significant challenges in providing timely medical care in nursing homes. Virtual visits were pivotal in providing both scheduled and urgent patient care in addition to in-person care when possible. These virtual visits could have been used to provide urgent medical care than the regular scheduled visits. We hypothesize that regular non-COVID-19-related virtual visits in the evaluated nursing home facilities were lower than COVID-19-related virtual visits during this period. The objective was to compare the frequency of COVID-19-related virtual visits with non-COVID-19-related virtual visits performed in three suburban nursing homes in Michigan from December 2020 through February 2022. Methods: Retrospective chart review of 283 patients, comprising 563 virtual visits. The most frequent ICD-10 diagnostic codes used by providers for primary encounters were analyzed for three participating facilities Results: Only 13.8% (78/563) of all virtual visits during the study period were for COVID-19 as a primary encounter. In total 86.1% (485/563) of visits were non-COVID-19 related, which comprised most frequently M6281 muscle weakness (45), E119 diabetes type with complications (20), NI86 end-stage renal disease (11), N390 urinary tract infection (10), G309 Alzheimer's disease (10), and I4891 unspecified atrial fibrillation (10). Conclusion: We found that the primary ICD-10 diagnosis codes for virtual COVID-19-related visits were significantly lower than non-COVID-19-related virtual visits in our study population. This trend could be associated with multiple system-based factors. Further studies to examine factors responsible for these findings are warranted.
BACKGROUND: Rising temperatures increase workers' risk of heat-related illnesses due to heat stress (HS). Chronic Kidney Disease of unknown etiology (CKDu) is rising in non-agricultural workers in hot climates. Dehydration, heat stress, and physical exertion can damage cashew workers' kidney health.
METHODS: In 2020-2021, 262 cashew workers in Cuddalore, Tamil Nadu were assessed for Wet Bulb Globe Temperature (WBGT), and job-specific American Conference of Governmental Industrial Hygienists standard was used to evaluate workload. "High heat-exposed" meant heat stress exceeded the Threshold Limit Value for safe manual work (27.5 °C for heavy and 28 °C for moderate physical activity). Heat Strain Indicators (HSIs) such as Tympanic Temperature (Ttemp), Sweat Rate (SwR), Urine Specific Gravity (USG), and urine dipstick parameters were measured in all workers, however serum creatinine was measured only in 100 workers. Glomerular Filtration Rate (eGFR) was calculated using the CKD-EPI equation. A standardized questionnaire assessed heat-related health symptoms.
RESULTS: Over 65% of workers experienced wet bulb globe temperature exposures exceeding the threshold limit value (Avg.- wet bulb globe temperature 30.4 °C ± 1.8 °C). Ninety-five percent of heat-exposed workers experienced at least one of the physiological heat strain indicators. The risk of urogenital symptoms was 7.7 times greater among high-heat-exposed workers (95% CI 3.4-17.1), which corroborates well with the measured post shift urine specific gravity (37%). Despite controlling for relevant confounders (age & gender), high-heat-exposed workers had 3.5-fold higher odds of eGFR < 90 ml/min/1.73 m2 compared to less-exposed workers (95% CI 1.1-10.6).
CONCLUSION: Persistent heat stress promotes heat-related disorders in cashew workers and lowers eGFR. This needs further investigation to determine its longer term effects on kidney function. Workplace cooling solutions that reduce heat stress are critically needed to protect the kidneys and ensure occupational health.
In this study of pharmacokinetic interactions, (1) the effect of ritonavir on the pharmacokinetics of amprenavir; (2) the effect of efavirenz on the pharmacokinetics of amprenavir and ritonavir, and (3) the effect of efavirenz on the pharmacokinetics of amprenavir and nelfinavir were examined. Twenty-two patients who have a viral burden of at least 500 copies/mL on combination therapy with a protease inhibitor for at least 20 weeks were to be enrolled to receive open-label treatment, 6 with abacavir 300 mg po BID, amprenavir 1200 mg po BID, ritonavir 200 mg po BID and efavirenz 600 mg po QD, 6 with abacavir 300 mg po BID, amprenavir 1200 mg po BID, ritonavir 500 mg po BID and efavirenz 600 mg po QD, and 10 with abacavir 300 mg po BID, amprenavir 1200 mg po BID, nelfinavir 1250 mg po BID and efavirenz 600 mg po QD. The groups enrolled sequentially: low-dose ritonavir combination group, then the full dose ritonavir combination group, and then the nelfinavir combination group. Subjects were seen at pre-entry, baseline (Day 1), and thereafter at study weeks 1 (serial sampling), 2 (serial sampling), 4, 8, 12, 16, 24 then every 8 weeks through one year. Patients discontinued current therapy and without a washout period began dosing. For the groups who will receive ritonavir, the schedule was: dose with abacavir and amprenavir and, after one-week, serial plasma sampling was performed for baseline amprenavir levels. Next ritonavir at the assigned dose was added (for the full-dose, there is a rapid dose escalation) and plasma sampling was repeated one week later; finally, efavirenz 600 mg once daily will be added and plasma sampling was again be repeated between 2 weeks after beginning the combination. For the nelfinavir group, the schedule was: dose with nelfinavir, amprenavir, and abacavir for one week and obtain serial plasma sampling, then add efavirenz for another week and obtain serial plasma sampling. Patients with a confirmed increase in viral burden of one log or greater from baseline will end study participation. The safety and antiviral activity of each combination were also assessed and continue to be assessed; toxicity management is outlined in the protocol. This study remains open in order to continue to provide these drugs to subjects who completed the original one-year study period and who wish to continue medications that appear, by viral load, to be of benefit to them.
A method for storing temporary data in a memory of a RFID tag associated with a consumable of a laboratory instrument for processing a reagent or biological sample is disclosed. The method comprises providing the RFID tag associated with the consumable. The RFID tag comprises a memory. The memory comprises a user memory configured to store user data and a system memory configured to store system data. The laboratory instrument writes the temporary data into the system memory. The temporary data are associated with a process to be carried out by the laboratory instrument. Further, a system comprising a laboratory instrument for processing a reagent or biological sample, a consumable and a RFID tag associated with the consumable is disclosed. The laboratory instrument is configured to carry out the method.
Obesity is a worldwide epidemic, with more than 2 billion people currently overweight and an additional 1.12 billion projected to be overweight by 2030. HCC (hepatocellular carcinoma) associated to obesity and its comorbidity is overcoming Hepatitis C Virus (HCV) related cancer and is already the leading cause of liver transplant in USA. HCC remains the sixth most common cancer in the world and the third cause of cancer-related death. Considering these epidemiological evidence, the incidence of MS-HCC (metabolic syndrome-related hepatocellular carcinoma) is expected to increase with huge cost efforts for the global healthcare system. The impaired performance status of patients with HCC and metabolic syndrome seems to explain high perioperative morbidity rate reported in literature. Literature reports several experiences of bariatric surgery combined to liver transplant for chronic liver disease related induced by non alcoholic steatohepatitis (NASH), performed before or after liver surgery, or even at the same time. Even if evidences are weak, outcomes reported seem to be promising. Since sleeve gastrectomy is not only a mere restrictive bariatric procedure, but it produces hormonal and metabolic changes, with the present study the investigators want to ascertain if sleeve gastrectomy at time of liver resection for MS-HCC (metabolic syndrome-related hepatocellular carcinoma) can modify short perioperative outcomes and long-term oncologic results.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: there is described an immunogen for making an immunogenic cancer composition free of DNA-binding function and all domains of a zinc finger, on the basis of polynucleotide coding a nonfunctional mutant form of a related molecule ("brother") of regulator of imprint sites (BORIS) of protein, polypeptide or peptide, containing amino acid sequence presented in the description. The immunogenic cancer composition contains aforementioned immunogen and an adjuvant chosen particularly from cytokine, chemokin, a costimulating molecule. There is described an expression vector containing polynucleotide, coding above-stated protein, e.g., in bacterial systems, mammal systems, in yeast or viral systems. The cancer vaccine under the invention contains polynucleotide (immunogen), additionally the adjuvant and, if necessary, a pharmaceutically acceptable carrier. The invention describes the method for of cancer immunisation of a mammal with using said immunogen on the basis of polynucleotide. ^ EFFECT: invention allows improving effectiveness of cancer prevention. ^ 28 cl, 7 dwg, 2 tbl, 1 ex
Exercises focusing on stretching and strengthening for all muscle groups will be performed at one-hour long sessions held 3 times a week for 8 weeks. Classes are led by trained exercise specialists.
Efficacy studies of moxifloxacin hydrochloride could not be conducted in humans with pneumonic plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals and supportive pharmacokinetic data in adult humans and animals.

A randomized, blinded, placebo-controlled study was conducted in an African Green Monkey (AGM) animal model of pneumonic plague. Twenty AGM (10 males and 10 females) were exposed to an inhaled mean (± SD) dose of 100 ± 50 LD50 (range 92 to 127 LD50) of Yersinia pestis (CO92 strain) aerosol. The minimal inhibitory concentration (MIC) of moxifloxacin for the Y. pestis strain used in this study was 0.06 mcg/mL. Development of sustained fever for at least 4 hours duration was used as the trigger for the initiation of 10 days of treatment with either a humanized regimen of moxifloxacin or placebo. All study animals were febrile and bacteremic with Y. pestis prior to the initiation of study treatment. Ten of 10 (100%) of the animals receiving the placebo succumbed to disease between 83 to 139 h (mean 115 ± 19 hours) post treatment. Ten of 10 (100%) moxifloxacin-treated animals survived for the 30-day period after completion of the study treatment. Compared to the placebo group, mortality in the moxifloxacin group was significantly lower (difference in survival: 100% with a two-sided 95% exact confidence interval [66.3%, 100%], p-value<0.0001).

The mean plasma concentrations of moxifloxacin associated with a statistically significant improvement in survival over placebo in an AGM model of pneumonic plague are reached or exceeded in human adults receiving the recommended oral and intravenous dosage regimens. The mean (± SD) peak plasma concentration (Cmax) and total plasma exposure defined as the area under the plasma concentration-time curve (AUC) in human adults receiving 400 mg intravenously were 3.9 ± 0.9 mcg/mL and 39.3 ± 8.6 mcg•h/mL, respectively [see Clinical Pharmacology (12.3)]. The mean (± SD) peak plasma concentration and AUC0-24 in AGM following one-day administration of a humanized dosing regimen simulating the human AUC0-24 at a 400 mg dose were 4.4 ± 1.5 mcg/mL and 22 ± 8.0 mcg·h/mL, respectively.
Pancreatic cysts are increasingly recognized as incidental lesions due to the widespread use of cross-sectional imaging techniques such as CT and MRI. Twenty percent of all pancreatic cysts are non-inflammatory cystic neoplasms, many of which are mucinous, and therefore have a significant potential for malignant transformation. The primary challenge facing clinicians is the inability of current standard diagnostic tests, including imaging and standard laboratory data, to accurately and reliably discriminate neoplastic from non-neoplastic, and benign from malignant cysts, particularly in patients without symptoms. Therefore, some patients with benign cysts undergo unnecessary costly surveillance and possible avoidable surgical resections, which is associated with high cost, significant morbidity and mortality, while some may not be as aggressively followed. The International Association of Pancreatology (IAP) has published guidelines on the management of the two main types of mucinous cystic lesions: intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs). (1) Although these guidelines emphasize the frequency of surveillance and outline the indications for resection, these guidelines have not yet been validated, and these guidelines presume the diagnosis of a mucinous neoplastic cyst has been confirmed prior to surgery. It is unlikely that guidelines that only use clinical and imaging will be able to accurately differentiate benign cysts from those that are pre-malignant or currently harbor malignancy. Hence, there is a critical need for a diagnostic model that more accurately diagnoses neoplastic mucinous and malignant pancreatic cysts as this will improve the management of many patients with pancreatic cysts.
For subjects who choose to have medication alone with no block for their routine care, there will be no changes to their care, which includes receiving the multimodal oral premedication of Celebrex 300-400mg, Tylenol 1000mg, and Oxycontin 10mg. They will be in an observational group only with no randomization.
Regorafenib 120 or 160 mg by mouth every day for the first 21 days of each 28-day cycle. If the dose is tolerated during the first 2 cycles in the 120 mg group, in Cycle 3 the 120 mg dose will be increased to 160 mg by mouth each day for the first 21 days of each 28-day cycle for 4 more cycles for a total of 6 cycles or 6 months of therapy.
The invention provides a method for manufacturing nanop articles of total alkaloids from Eomecon chionantha Hance. The steps for the preparation are as follows: a) Comminuting the medicinal parts of Eomecon chionantha Hance and mixing with an alkaline substance, adding water to mix uniformly, and then standing overnight; b) adjusting the pH of the mixture, collecting and drying the resulting precipitate, and then extracting with an alcohol, followed by concentrating and filtrating; c) refrigerating the filtrate and spraying into a supercritical crystallization kettle countercurrently to prepare nanoparticles; d) collecting nanoparticles at the bottom as the nanometer particles of total alkaloids from Eomecon chionantha Hance. This method is mainly to extract and purify the alkaloids from the active parts in the Eomecon chionantha Hance, wherein the alkaloids are converted into ion pairs and filtered. The content of the total alkaloids in the product reaches 60% or more, and the diameter of the main portion of the obtained nanoparticles is 1-15 11m and the smallest diameter is 500nm. The process is environmentally friendly and non-pollution, simple and suitable for large-scale production. Nanoparticles of the total alkaloids have high absorptivity and high bioavailability, and will be more widely used in the ﬁelds of feed additives, medicine and food.
Type 2 diabetes mellitus is regarded as one of the most prevalent disease of the adult population. In many developing countries, this condition is regarded as major public health problem. Type 2 diabetes is a metabolic disorder characterized by high blood glucose related with a condition of insulin resistance and relative insulin deficiency. As Diabetes progresses, medications are necessary to control glucose levels.

The aim of this study was to investigate whether the infusion of a medicinal plant (Cissus verticillata L.) would be as effective as a regular drug (glibenclamide) in reducing glucose levels in blood and saliva of type 2 Diabetes patients. Several medicinal plants have been used as potential medication for controlling glucose levels in Diabetes patients. Few studies have explored this effect related to Cissus verticillata L.infusion, though it has been indicated by folk medicine of some Latin American countries.
Heart disease, including coronary heart disease (CHD) and cardiovascular disease (CVD), is a serious health problem in the United States. It is the leading cause of death in this country, and each year almost 700,000 people die from the disease. Risk factors for heart disease include high blood pressure, high cholesterol levels, tobacco use, diabetes, and history of a prior heart attack. It has been shown that young and middle aged adults with few risk factors experience a lower incidence of heart disease, lower Medicare costs, and longer lives than those with more risk factors. However, it is not known how having a low risk for heart disease at a young age affects health-related outcomes in older age. It may be possible that a low risk for developing heart disease in younger years results in healthier aging than does a higher risk. This study will examine former participants of the Chicago Heart Association (CHA) study who are now 65 to 84 years old. The purpose of this study is to determine how risk factors for heart disease in young adulthood and middle age are related to healthy aging.

This study will enroll 1500 people who participated in the CHA study from 1967 to 1973 and who are still living in the Greater Chicagoland area. Six hundred former participants who had a low risk of developing heart disease and 900 former participants who had a high risk of developing heart disease will be enrolled. Participants will attend one study visit that will include medical history interviews and questionnaires, a physical examination, blood pressure measurements, blood and urine collection, and an electrocardiogram (ECG) to measure the electrical activity of the heart. Blood samples will be collected and stored for future genetic testing. Participants will undergo physical functioning performance tests on balance, leg strength and coordination, grip strength, and endurance. They will also undergo a computed tomography chest scan to measure the amount of calcium in the arteries of the heart and ultrasound scans of the arteries in the neck to measure artery size and function.
Alzheimer's disease (AD) is a prevalent neurodegenerative disease characterized by progressive cognitive and functional decline. Nearly all patients with AD develop neuropsychiatric symptoms (NPSs). Agitation is one of the most distressing and challenging NPS. Brexpiprazole is an oral antipsychotic and is the first approved pharmacologic agent in the United States for the treatment of agitation associated with dementia due to AD. Its effect is thought to be from its partial serotonin 5-HT1A and dopamine D2 receptor agonist activity and serotonin 5-HT2A receptor antagonism. Brexpiprazole is a maintenance medication, and it should not be used "as needed" or as a "PRN" treatment for breakthrough agitation. Brexpiprazole is a major substrate of CYP2D6 and CYP3A4. Dose adjustments may be required for drug interactions or impaired renal or hepatic function. Clinical trials found brexpiprazole 2 to 3 mg/d demonstrated significant improvements in agitation, with brexpiprazole showing an approximate 5-point greater reduction on change in the Cohen-Mansfield Agitation Inventory total score at week 12 from baseline compared with placebo. Brexpiprazole is generally well tolerated and safe, and common adverse reactions when used for this indication include dizziness, headaches, insomnia, nasopharyngitis, somnolence, and urinary tract infections. Like other antipsychotics used for agitation in AD, brexpiprazole is associated with higher mortality rates compared with placebo. In a long-term care setting, there are several considerations for its use. Benefits include an oral agent that is well tolerated and clinical data showing statistically significant effects on agitation. However, brexpiprazole has not been studied in head-to-head clinical trials against other antipsychotics, and there are differing opinions if the agitation score reductions translate to a clinically meaningful difference. The approval of brexpiprazole signals favorably for upcoming agents for this indication, including escitalopram and dextromethorphan-bupropion. Both escitalopram and dextromethorphan-bupropion are currently undergoing clinical trials.
BACKGROUND: Understanding pain and its mechanisms can play an important role in (post-) cancer rehabilitation. In order to test patient's knowledge of pain, the Revised Neurophysiology of Pain Questionnaire was developed and translated into Dutch (RNPQ-NL). However, its psychometric properties have not been examined yet.
OBJECTIVE: The goal is to examine the psychometric properties of the RNPQ-NL as a tool to measure the knowledge of pain; in addition, its cross-cultural validity between Belgian and Dutch participants is examined.
METHODS: 277 persons from Belgium and the Netherlands participated in this study. Cancer patients and survivors (CPaS) (n = 115) were compared to a group of experts with medical training (n = 97). Highly educated individuals without medical background (n = 65) served as control group. The RNPQ-NL was filled out twice and scores analysed in accordance with the COSMIN-recommendation for assessing the methodological quality of studies on measurement properties of health status instruments.
RESULTS: The RNPQ-NL was able to distinguish between high and low knowledge of pain. The CPaS group scored significantly lower on the RNPQ-NL compared to the expert group (p < 0.001), but not in comparison to the control group (p=1.00). The Belgian CPaS scored lower than the Dutch CPaS (p=0.001), with a medium effect size (d = 0.481), showing acceptable cross-cultural validity. The Cronbach's α was 0.625, showing some heterogeneity of the items. The test-retest reliability was adequate (ICC = 0.794).
CONCLUSION: This study supports the interpretability, test-retest reliability, discriminative, and cross-cultural validity of the RNPQ-NL. Internal consistency is suboptimal but acceptable for measuring the knowledge of pain in CPaS.
Human serum albumin, at 2 g/kg, administered over 2 hours by intravenous infusion, will be compared to placebo (isovolumic normal saline) among patients with acute ischemic stroke. All patients will have a baseline stroke severity measured as NIH Stroke scale score \> 5. Patients will treated according to the best standard of care including concurrent treatment with intravenous or intra-arterial thrombolysis where appropriate. The primary outcome will be determined at 3 months. The primary hypothesis is that, using the composite outcome of a modified Rankin score 0-1 or NIH stroke scale score 0-1 at 3 months (or both), the proportion of patients with improved outcomes will be greater by 10% or more in the active treatment group. \[The current trial is termed "Part 2" and incorporates revisions to the initial protocol that were instituted after the Data Safety Monitoring Board (DSMB) suspended subject recruitment because of a safety concern after 434 subjects had been enrolled. The protocol revisions of Part 2 resulted from the study team's thorough review of the Part-1 safety data and were designed to optimize safety going forward.\]
As an intervention to this group, rosemary application will be made by inhalation. Participants will apply rosemary oil in half an hour before going to bed every night for a month under the supervision of a relative. The application will be done by dripping three drops on cotton, holding it 5-10 cm away from the nose for five minutes and breathing normally.